Simpson Thacher is representing the EQT VIII fund and Aldevron in connection with its agreement to sell Aldevron to Danaher Corporation for an enterprise value of $9.6 billion. EQT acquired a majority interest in Aldevron in 2019, investing alongside TA Associates, founders and management. The transaction is subject to customary conditions, including receipt of applicable regulatory approvals.
Founded in 1998 by Michael Chambers and John Ballantyne, Aldevron is a leading global provider of high-quality plasmid DNA, mRNA and recombinant proteins used in vaccines, gene and cell therapy, gene editing and diagnostic applications.
The Simpson Thacher team includes Patrick Naughton, Naveed Anwar, Erica Egenes, Megan Whitman, Fiona Gillan, Brittani Frink, Audrey Kim and Omar Kanjwal (M&A); Sara Razi, Kelly Karapetyan, Joshua Hazan and Nicholas Ingros (Antitrust); Jonathan Goldstein, Joseph Tootle and Lina Pan (Tax); Jennifer Hobbs and Eli Isak (Credit); David Rubinsky, Jamin Koslowe, Patricia Adams and Guanxiong Xu (Executive Compensation and Employee Benefits); Lori Lesser and Corina McIntyre (Intellectual Property); Dennis Loiacono (Real Estate); and Adeeb Fadil and Tim Mulvihill (Environmental). Summer Associate Siunik Moradian provided valuable assistance.